Close Menu

NEW YORK (GenomeWeb) – Foundation Medicine expects to grow its clinical testing business this year while continuing to expand its pharma collaborations, following the anticipated final national coverage determination (NCD) for its FoundationOne CDx test by the Centers for Medicare and Medicaid Services later this month.

During a conference call yesterday to discuss the firm's fourth quarter earnings, CEO Troy Cox and CFO Jason Ryan provided an outline of the firm's plans and strategy for 2018.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.